Recent News

• 03.19.2026 - Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• 03.03.2026 - Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
• 03.02.2026 - Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
• 02.25.2026 - Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
• 02.20.2026 - Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
• 02.02.2026 - Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Recent Filings

• 03.19.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.19.2026 - 8-K Current report
• 03.19.2026 - EX-99.1 EX-99.1
• 03.06.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 03.02.2026 - EX-99.1 EX-99.1
• 03.02.2026 - 8-K Current report
• 02.25.2026 - 8-K Current report
• 02.25.2026 - EX-99.1 EX-99.1
• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - EX-99.1 EX-99.1